New York, USA – July 21, 2021 – On July 9, the FDA granted routine approval to the ADC enfortumab vedotin-ejfv (PADCEV, Astellas Pharma US, Inc.) and expanded its indications for the treatment of locally advanced or metastatic urothelial carcinoma (UC) adult patients who are not eligible for cisplatin chemotherapy and have received first-line or multi-line therapy previously. The R&D fever of ADC is rushing and it is encouraging that continuous breakthroughs occur in recent years. As a biotech CRO of some renown, Creative Biolabs can give a hand to clients’ ADC projects with its one-stop solutions.
An ADC development project initiates with selecting antibody and payload, which will then be combined with a suitable linker through appropriate conjugation methods. A group of “draft” ADC molecules is obtained thereby, which needs to be fully evaluated to determine the final ADC candidates for delivery.
In vitro analysis provides an overall evaluation into biochemical character, efficacy, and performance, which not only makes clear the structure and DAR, but also enables elaborate ADC cytotoxicity detection and estimation on performance in vitro.
The in vivo analysis provides a more reliable and comprehensive ADC characterization, covering ADME, efficacy, immunogenicity, and safety. Creative Biolabs employed various species such as rodents and non-human primates to help provide the most intuitive report of an ADC’s pharmacokinetic properties.
This recent breakthrough has won ADC considerable market share, which can be judged from more and more inquiries received by Creative Biolabs.
“ADCs are gaining a ratio in the field of tumor immunotherapy,” said a scientist, “and we are happy to see our clients are making progress with their studies.”
At Creative Biolabs, a group of scientists who major in chemical conjugation subjects and drug discovery gather, providing one-stop solutions regarding ADC development and with the help of high-end platforms and profound experience in payload chemistry, they have developed antibodies, customized ADCs, linker products, payload, etc., which are readily available for global delivery. Visit https://www.creative-biolabs.com/adc to learn more.
Creative Biolabs is specialized in advanced antibody biochemistry and engineering, which, after years of exploration and expansion, has extended the research and service capacity to the entire new drug discovery and development pipeline, especially in targeted immunotherapy and antibody-drug conjugate (ADC). A team of professors at Creative Biolabs provides one-stop solutions relevant to ADC, covering not only ADC development and evaluation but also standard ADC-related products to global customers, as a support of their study projects.